Skip to main content

Advertisement

Fig. 2 | Clinical and Translational Medicine

Fig. 2

From: PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma

Fig. 2

Molecular mechanisms underlying the dexamethasone insensitivity of PBMCs in severe asthma. a HDAC2 activity in PBMCs from normal controls and patients with mild/moderate or severe asthma [*p < 0.05; **p < 0.01, n = 12, 12, 10 (normal, mild/moderate asthma, severe asthma, respectively)]. b The gene expression of nuclear signaling transcription factors (p-NF-κB, p-c-FOS, p-c-JUN) in PBMCs from normal controls and patients with mild/moderate or severe asthma was analyzed by western blotting. The lower right panel shows the quantitative densitometric analysis. Representative data from at least 3 independent experiments are shown [*p < 0.05; **p < 0.01; n = 12, 12, 10 (normal, mild/moderate asthma, severe asthma, respectively)]

Back to article page